| HIF inhibitors: status of current clinical development J Fallah, BI Rini Current oncology reports 21, 1-10, 2019 | 292 | 2019 |
| FDA approval summary: belzutifan for von Hippel-Lindau disease–associated tumors J Fallah, MH Brave, C Weinstock, GU Mehta, D Bradford, H Gittleman, ... Clinical Cancer Research 28 (22), 4843-4848, 2022 | 58 | 2022 |
| FDA approval summary: lutetium Lu 177 vipivotide tetraxetan for patients with metastatic castration-resistant prostate cancer J Fallah, S Agrawal, H Gittleman, MH Fiero, S Subramaniam, C John, ... Clinical Cancer Research 29 (9), 1651-1657, 2023 | 56 | 2023 |
| Human immunodeficiency virus‐associated lymphomas in the antiretroviral therapy era: analysis of the National Cancer Data Base AJ Olszewski, J Fallah, JJ Castillo Cancer 122 (17), 2689-2697, 2016 | 54 | 2016 |
| Type D personality and quality of life in patients with irritable bowel syndrome RB Sararoudi, H Afshar, P Adibi, H Daghaghzadeh, J Fallah, ... Journal of research in medical sciences: the official journal of Isfahan …, 2011 | 37 | 2011 |
| Diagnostic and therapeutic splenectomy for splenic lymphomas: analysis of the National Cancer Data Base J Fallah, AJ Olszewski Hematology 24 (1), 378-386, 2019 | 32 | 2019 |
| Therapy and outcomes of primary central nervous system lymphoma in the United States: analysis of the National Cancer Database J Fallah, L Qunaj, AJ Olszewski Blood advances 1 (2), 112-121, 2016 | 31 | 2016 |
| On the shoulders of giants: the evolution of renal cell carcinoma treatment—cytokines, targeted therapy, and immunotherapy JP Dutcher, R Flippot, J Fallah, B Escudier American Society of Clinical Oncology Educational Book 40, 418-435, 2020 | 29 | 2020 |
| Survival outcomes in older men with non-metastatic castration-resistant prostate cancer treated with androgen receptor inhibitors: a US Food and Drug Administration pooled … J Fallah, L Zhang, A Amatya, Y Gong, B King-Kallimanis, V Bhatnagar, ... The Lancet Oncology 22 (9), 1230-1239, 2021 | 12 | 2021 |
| Clinical outcomes of the combination of bevacizumab and ttfields in patients with recurrent glioblastoma: Results of a phase II clinical trial. J Fallah, RT Chaudhary, LR Rogers, W Wei, CJ Brewer, DM Peereboom, ... Journal of Clinical Oncology 38 (15_suppl), 2537-2537, 2020 | 12 | 2020 |
| Myeloid-derived suppressor cells in nonmetastatic urothelial carcinoma of bladder is associated with pathologic complete response and overall survival J Fallah, CM Diaz-Montero, P Rayman, W Wei, JH Finke, JS Kim, ... Clinical Genitourinary Cancer 18 (6), 500-508, 2020 | 10 | 2020 |
| Prostate cancer theranostics: concurrent approvals by the Food and Drug Administration of the first diagnostic imaging drug indicated to select patients for a paired … AA Hofling, AF Fotenos, G Niu, J Fallah, S Agrawal, SJ Wang, L Marzella Journal of Nuclear Medicine 63 (11), 1642-1643, 2022 | 9 | 2022 |
| Sex-specific differences in low-grade glioma presentation and outcome S Tewari, MC Tom, DYJ Park, W Wei, ST Chao, SY Jennifer, JH Suh, ... International Journal of Radiation Oncology* Biology* Physics 114 (2), 283-292, 2022 | 6 | 2022 |
| safety and efficacy of bevacizumab plus TTFields in patients with recurrent glioblastoma (GBM): Data from a phase II clinical trial J Fallah, R Chaudhary, L Rogers, WA Wei, C Brewer, D Peereboom, ... Neuro-Oncology 21 (Supplement_6), vi18-vi18, 2019 | 5 | 2019 |
| Small bowel adenocarcinoma as the cause of gastrointestinal bleeding in celiac disease: a rare malignancy in a common disease J Fallah, ME Afari, AC Cordova, AJ Olszewski, T Minami Case reports in oncological medicine 2015, 2015 | 5 | 2015 |
| FDA Approval Summary: Belzutifan for VHL Disease Tumors—Response J Fallah, C Weinstock, GU Mehta, MH Brave, WF Pierce, R Pazdur, A Nair, ... Clinical Cancer Research 29 (3), 685-685, 2023 | 4 | 2023 |
| Identifying prostate surface antigen patterns of change in patients with metastatic hormone sensitive prostate cancer treated with abiraterone and prednisone IY Sheng, J Fallah, R Gupta, H Li, K Allman, A Martin, P Barata, ... Targeted Oncology 15, 477-483, 2020 | 4 | 2020 |
| A randomized phase 2 open label study of nivolumab plus standard dose bevacizumab versus nivolumab plus low dose bevacizumab in recurrent glioblastoma (GBM) M Ahluwalia, J Fallah, D Peereboom, C Schilero, A Ali, D Forst, E Wong, ... Neuro-Oncology 21 (Supplement_6), vi220-vi220, 2019 | 4* | 2019 |
| The role of immunotherapy in the management of patients with renal cell carcinoma and brain metastases J Fallah, M Ahluwalia Annals of Translational Medicine, 1-5, 2019 | 4 | 2019 |
| Survival claims from observational data on cancer therapy AJ Olszewski, J Falah, JJ Castillo J Clin Oncol 34 (12), 1425-1427, 2016 | 4 | 2016 |
